Aclaris Therapeutics Liabilities 2025

Aclaris Therapeutics Aktienanalyse

What does Aclaris Therapeutics do?

Aclaris Therapeutics Inc was founded in 2012 and is based in Wayne, Pennsylvania. The company focuses on the development and marketing of innovative solutions for the treatment of skin problems and other diseases that significantly impact the quality of life of those affected. Aclaris' business model is based on the research and development of new therapies that address various medical problems and conditions. The company employs a combination of internal research projects and the acquisition of promising products and pipeline assets from third-party companies. Aclaris is divided into different business segments that focus on various medical issues and conditions. One important area is dermatology, where the company has developed several innovative products and therapies. This includes RHOFADE® (Oxymetazoline Hydrochloride), a topical medication for the treatment of rosacea. The novel product A-101, used for the treatment of seborrheic keratosis, has also been established in the market. In the field of oncological dermatology, Aclaris has a promising pipeline focused on the development of drugs for the treatment of actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma. The company collaborates closely with scientists and research institutions to develop innovative solutions that can revolutionize the pharmaceutical market. Another area that Aclaris focuses on is immunology, including the development of new therapies for the treatment of inflammatory diseases such as alopecia areata, an autoimmune disease that causes hair loss. Aclaris has already made significant progress in this area and is conducting clinical studies to demonstrate the effectiveness of its products in treating this condition. In addition to the development of innovative therapies, Aclaris also collaborates closely with other companies and research institutions to develop platform technologies that can accelerate and simplify the development of new drugs. This includes state-of-the-art analytical methods and the development of new molecules that specifically target certain diseases. Aclaris' business model has proven successful in recent years. The company combines internal research projects with the acquisition of promising pipeline assets from third-party companies to expand its portfolio and pipeline. This approach allows Aclaris to quickly respond to changing market conditions and patient needs, positioning themselves as a leading player in the pharmaceutical market. Aclaris' products have already improved many lives and successfully treated numerous patients with various medical problems. The company aims to achieve sustainable improvement in the quality of life of patients and continuously develop new innovative solutions to secure a leading position in the highly competitive pharmaceutical market. Aclaris Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Aclaris Therapeutics's Liabilities

Aclaris Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Aclaris Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Aclaris Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Aclaris Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Aclaris Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Aclaris Therapeutics stock

What is the level of liabilities of Aclaris Therapeutics this year?

Aclaris Therapeutics has a debt balance of 40.23 M USD this year.

What were the liabilities of Aclaris Therapeutics compared to the previous year?

The liabilities of Aclaris Therapeutics have increased by -29.43% dropped compared to the previous year.

What are the consequences of high debt for investors of Aclaris Therapeutics?

High liabilities can pose a risk for investors of Aclaris Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Aclaris Therapeutics?

Low liabilities mean that Aclaris Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Aclaris Therapeutics affect the company?

An increase in liabilities of Aclaris Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Aclaris Therapeutics affect the company?

A decrease in the liabilities of Aclaris Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Aclaris Therapeutics?

Some factors that can influence the liabilities of Aclaris Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Aclaris Therapeutics so important for investors?

The liabilities of Aclaris Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Aclaris Therapeutics take to modify the liabilities?

To change its liabilities, Aclaris Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Aclaris Therapeutics pay?

Over the past 12 months, Aclaris Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aclaris Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aclaris Therapeutics?

The current dividend yield of Aclaris Therapeutics is .

When does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aclaris Therapeutics?

Aclaris Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aclaris Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aclaris Therapeutics located?

Aclaris Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aclaris Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aclaris Therapeutics from 1/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/29/2025.

When did Aclaris Therapeutics pay the last dividend?

The last dividend was paid out on 1/29/2025.

What was the dividend of Aclaris Therapeutics in the year 2024?

In the year 2024, Aclaris Therapeutics distributed 0 USD as dividends.

In which currency does Aclaris Therapeutics pay out the dividend?

The dividends of Aclaris Therapeutics are distributed in USD.